The global sickle cell disease drug market is anticipated to grow at a considerable CAGR during the forecast period. The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in June 2020, Emmaus Medical Inc. has received approval from the Israeli Ministry of Health for the commercial distribution of Endari in Israel. Endari is an L-Glutamine oral powder that is used to treat acute complications of sickle cell disease in adults and children age 5 years and older. Further, in October 2020, Medunik USA Inc. launched Siklos for pediatric patients with sickle cell diseases. Siklos is a 100 mg film-coated tablet, that is used to reduce the painful crisis caused by sickle cell disease. According to Medunik USA Inc., skilos are anticipated to reduce the need for blood transfusions. Similarly, in October 2020, the European Commission (EC) has approved the Adakveo drug for commercialization.
Browse the full report description “Global Sickle Cell Disease Drug Market Size, Share &Trends Report By Treatment (Blood Transfusion, Bone Marrow Transplant, and Pharmacotherapy) and by End User (Hospitals, Speciality Clinics, and others) Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/sickle-cell-disease-drug-market
Moreover, in October 2020, the US Food and Drug Administration has approved Rivipansel (GMI-1070) for the treatment of sickle cell disease. Rivipansel is developed by GlycoMemitics in partnership with Pfizer. The revipansel is used to treat the pain crisis, sickle cell disease, and sickle cell-related disorders. Further in January 2022, Sangamo Therapeutics Inc. has developed SAR445136, a zinc finger nuclease gene-edited cell therapy. Sanofi will be transitioning its rights and obligation related to SAR445136. In November 2019, Novartis AG has launched Adkaveo. Adakveo (Crizanlizumab –tmca) is indicated to reduce the Vasco-occlusive crisis in adults and pediatric patients aged 16 years and older.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- Novartis AG, Global Blood Therapeutics Inc., Medunik USA Inc., Bristol-Myers Squibb Co, Emmaus Medical Inc., and more
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Sickle Cell Disease Drug Market Report Segment
By Treatment
By End-User
Global Sickle Cell Disease Drug Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/sickle-cell-disease-drug-market